<DOC>
	<DOCNO>NCT02900443</DOCNO>
	<brief_summary>Rationale : Current standard therapy autoimmune hepatitis consist combination prednisolone azathioprine . However , significant proportion patient respond , intolerant , azathioprine . Mycophenolate mofetil ( MMF ) surpass azathioprine therapy prevent organ transplant rejection sometimes use alternative option autoimmune hepatitis . Several case series one prospective study document efficacy safety mycophenolate mofetil induction therapy autoimmune hepatitis . Robust evidence formal randomize clinical trial lacking . Objective : To assess efficacy safety mycophenolate mofetil induction therapy patient treatment naive autoimmune hepatitis . Study design : Multicenter , randomise , open-label intervention study Study population : Patients newly diagnose autoimmune hepatitis need induction therapy accord current guideline . Intervention : The intervention group receive oral mycophenolate mofetil 24 week . The control group treat azathioprine 24 week . Both group treat steroid induction closely follow schedule recent Clinical Practice Guidelines European Association Study Liver ( EASL ) . Main study parameters/endpoints : The primary outcome proportion patient remission , define normalization serum alanine transaminase ( ALT ) immunoglobulin G ( IgG ) level 24 week treatment , per treatment group . Secondary endpoint include safety tolerability mycophenolate mofetil , time remission , change Model For End-Stage Liver Disease ( MELD ) -score ( component bilirubin , INR , creatinine ) , albumin , pseudocholinesterase N-terminal procollagen-III-peptide , ELF ( Enhanced Liver Fibrosis ) -score aspect quality life . In sub-study , drug level measure .</brief_summary>
	<brief_title>Mycophenolate Mofetil Versus Azathioprine Treatment Naive Autoimmune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Probable definite diagnosis autoimmune hepatitis accord International Autoimmune Hepatitis Study Group criteria First presentation AIH require treatment accord current EASL guideline Age â‰¥ 18 year Must provide inform consent agree comply trial protocol Overlap syndrome Primary Sclerosing Cholangitis ( PSC ) Primary Biliary Cholangitis ( PBC ) ( Paris criterion , strong positive AntiMitochondrial Antibodies ( AMA ) , past liver biopsy cholangiographic finding compatible PBC PSC ) . Presentation acute liver failure , define presence hepatic encephalopathy coagulopathy ( INR &gt; 1.5 ) Current treatment prednisone/prednisolone and/or immunosuppressive medication indication autoimmune hepatitis Current systemic infection Other clinically significant medical condition could interfere trial If female childbearing potential : know pregnancy , unwilling practice anticontraceptive measure . History noncompliance medical regimen , patient consider potentially unreliable unable participate Mental instability incompetence , validity inform consent compliance trial uncertain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>